BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$8.50 | $0.27 | Beat |
| May 15, 2026 | -$10.00 | -$6.18 | Beat |
| Mar 31, 2026 | -$12.00 | -$8.00 | Beat |
| Nov 13, 2025 | -$0.31 | -$13.50 | Miss |
| Aug 7, 2025 | -$0.29 | -$16.00 | Miss |
| May 6, 2025 | -$0.29 | -$13.00 | Miss |